GOSS: SEC Form 8-K filed by Gossamer Bio Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for GOSS
Across the 27 sessions after earlier GOSS headlines, the stock closed higher 12 times and lower 14 times, with a median move of 3.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | GOSS | SPY |
|---|---|---|---|
| Oct 13, 2026 | Chardan Capital Markets initiated coverage on Gossamer Bio with a new price target | +5.2% | -0.0% |
| Sep 24, 2026 | Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension | -0.5% | -0.1% |
| Sep 17, 2026 | Gossamer Bio Appoints Greg Ciongoli to Board of Directors | +8.9% | +1.1% |
| Sep 11, 2026 | Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split | -5.8% | +0.9% |
| Sep 9, 2026 | Gossamer Bio Announces 1-for-80 Reverse Stock Split | -11.2% | -0.5% |
| Sep 4, 2026 | Gossamer Bio to Present at Cantor Global Healthcare Conference | -0.2% | -0.4% |
Quantisnow market dataNASDAQ
GOSS
Gossamer Bio Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2019
Get push alerts for GOSS
Full GOSS profile on Quantisnow Follow GOSS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time